Selected article for: "disease progression and HCV disease"
Author: De Re, Valli; De Zorzi, Mariangela; Caggiari, Laura; Lauletta, Gianfranco; Tornesello, Maria Lina; Fognani, Elisa; Miorin, Marta; Racanelli, Vito; Quartuccio, Luca; Gragnani, Laura; Russi, Sabino; Pavone, Fabio; Ghersetti, Michela; Costa, Elena Garlatti; Casarin, Pietro; Bomben, Riccardo; Mazzaro, Cesare; Basaglia, Giancarlo; Berretta, Massimiliano; Vaccher, Emanuela; Izzo, Francesco; Buonaguro, Franco Maria; De Vita, Salvatore; Zignego, Anna Linda; De Paoli, Paolo; Dolcetti, Riccardo
Title: HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2
  • Cord-id: z0iwz1e8
  • Document date: 2016_5_11
    • ID: z0iwz1e8
    Snippet: To explore the relationship between innate immunity and hepatitis C Virus (HCV) in determining the risk of cirrhosis (CIR), hepatocellular carcinoma (HCC), mixed cryoglobulinemia syndrome (MCS) and non-Hodgkin lymphoma (NHL), we investigated the impact of the toll-like receptor-2 (TLR2) and interleukin-28B (IL28B) genetic variants. TLR2 −174 del variant was associated with TLR2 expression and with specific downstream molecules that drive the expression of different interleukins; rs12979860 Il2
    Document: To explore the relationship between innate immunity and hepatitis C Virus (HCV) in determining the risk of cirrhosis (CIR), hepatocellular carcinoma (HCC), mixed cryoglobulinemia syndrome (MCS) and non-Hodgkin lymphoma (NHL), we investigated the impact of the toll-like receptor-2 (TLR2) and interleukin-28B (IL28B) genetic variants. TLR2 −174 del variant was associated with TLR2 expression and with specific downstream molecules that drive the expression of different interleukins; rs12979860 Il28B was important in response to interferon-treatment and in spontaneous clearance of HCV. The risk for liver and lymphoproliferative diseases in HCV progression was clarified by stratifying 862 HCV-positive patients into groups based on liver (CIR, HCC) and lymphoproliferative HCV-related diseases (MCS, NHL) and compared with chronic HCV (CHC) infection. Analysis of TLR2-IL28B haplotypes showed an association of wild type haplotype with the lymphoproliferative diseases (OR 1.77, p = 0.029) and a slight increase in HCV viral load (HR 1.38, p = 0.054). Wild type haplotype (TLR2 ins/ins- IL28B C/C) was also found associated with older age in patients with an hepatic diseases (in CIR and in HCC p = 0.038 and p = 0.020, respectively) supporting an effect of innate immunity in the liver disease progression. TLR2 and IL28B polymorphisms in combination showed a role in the control of HCV viral load and different HCV disease progression.

    Search related documents:
    Co phrase search for related documents
    • absence presence and additional factor: 1
    • absence presence and liver cancer: 1
    • absence presence and liver damage: 1, 2
    • absence presence and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and liver infection: 1
    • absence presence and liver injury: 1, 2, 3, 4, 5, 6
    • absence presence and liver tissue: 1, 2, 3
    • absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activator signal transducer and liver disease: 1
    • additional factor and liver damage: 1, 2
    • additional factor and liver disease: 1, 2, 3, 4, 5, 6
    • additional factor and liver infection: 1, 2, 3
    • additional factor and liver infection disease: 1
    • additional factor and liver injury: 1
    • additional factor and liver tissue: 1
    • additional factor and logistic regression: 1, 2, 3, 4, 5
    • additional factor and logistic regression analysis: 1, 2
    • additive genetic model and liver disease: 1